Ms. Andreas’ biopharma career spans almost 20 years in multiple cross-functional roles across the drug development process, maintaining a primary focus in oncology at small to midsize companies. Prior to joining Context, Ms. Andreas was Vice President, Clinical Operations at Avenge Bio where she was responsible for oversight of all clinical trial activities, clinical operations strategy, planning, and execution for a first in human allogeneic cell therapy for ovarian cancer. Previously, at Boston Pharmaceuticals, Ms. Andreas led clinical operations and program management for zeteletinib through proof of concept and other oncology assets through early development. Ms. Andreas also spent 10 years with Merrimack Pharmaceuticals in various roles advancing multiple oncology and immunology-focused assets and three years at ArQule advancing the company's first early-stage studies. Ms. Andreas holds a bachelor’s degree in biology from Colby College and a Master of Science from Tufts University School of Medicine.

Mr. Beck joined Context in January 2022 as SVP of Operations. He is a pharmaceutical leader with a proven track record in strategy execution and program management capabilities. His 30-year career spans private, public, startup and high growth Pharmaceutical and Biotech companies. Prior to joining the Company, Mr. Beck served as Vice President Program Management at Galera Therapeutics where he was responsible for the design and implementation of an operations management methodology that drove execution across R&D, CMC, and Commercial functions. His other startup experience includes VP of Program Management roles at Aevi Genomics, and Formular Pharmaceuticals. Mr. Beck also held program management leadership positions at Shire Pharmaceuticals, Merck and Co., and AstraZeneca.

Mr. Beck holds a B.S. Business Administration degree from Drexel University and an MBA from Pennsylvania State University.

Eric Butz brings more than 25 years of innovative research and team leadership in academic and biotechnology settings. Dr. Butz received his Ph.D. in Microbiology at the University of Minnesota where he worked on acute virus infection-induced immune suppression. At the Howard Hughes Medical Institute at the University of Washington, he made seminal observations on the nature and magnitude of anti-viral CD8 T cells responses to acute virus infections working in the lab of Michael Bevan. Thereafter, he joined Immunex where his work on T-cell priming and T cell/dendritic cell interactions and dendritic cell biology led to several patents. After Immunex was acquired by Amgen, he joined the Inflammation group, where he led projects ranging from target discovery and validation through phase II clinical development, including AMG 714, a first in class IL-15-neutralizing antibody. His research employed a wide variety of in vivo and in vitro techniques and gene expression analysis systems and was focused largely on inflammatory diseases, including work on immuno-oncology strategies. He has worked with modalities including antibodies, soluble receptors, small molecules, antibody-drug conjugates and novel strategies to alter cytokine-receptor interactions and to improve cell specific drug targeting.

In 2014 he founded Cascade Immunobiology, LLC, a biotechnology consulting service. He is also the Head of Biomarkers and a consulting immunologist for Celimmune in their planning and execution of a first of its kind phase II clinical trial the treatment of type II refractory celiac disease, an in situ intestinal T cell lymphoma. He is also an Affiliate Associate Professor in the University of Washington Department of Medicine, Division of Rheumatology, where he serves as an external consultant, and is an affiliate member of the Center for Innate Immunity and Immune Disease.

Dr. Dansky Ullmann brings over 30 years of experience in early and late-stage oncology therapeutics development. Most recently, he was the CMO at Avenge Bio, where Dr. Dansky Ullmann guided the clinical advancement of AVB-001 allogeneic cell therapy for ovarian cancer. Prior to Avenge, Dr. Dansky Ullmann was CMO at MaxCyte where he was responsible for the development of the CARMA™ chimeric antigen receptor (CAR) therapy program, including MCY-M11, a mesothelin-targeting CAR therapy. Previously, he was the Senior Vice President, Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra® through FDA approval and eganelisib through first in human studies. Earlier, he was Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann was a Senior Investigator in the Cancer Therapy Evaluation Program at the National Cancer Institute, where he was involved in the strategic development of novel agents through Phase 1-3 clinical trials. Dr. Dansky Ullmann earned his M.D. at the School of Medicine, Universidad de Buenos Aires and completed his medical oncology training at Guemes Private Hospital, Buenos Aires.

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company.  Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis.  In addition to his role at Context, Martin is the Director of Philly BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

+ LinkedIn

Chief Legal Officer

Jeffrey Liebman currently serves as an Accounting Manager at Context Therapeutics. He brings over seven years of finance and accounting experience, with a particular focus on budgeting, forecasting, and revenue recognition. Prior to joining the Company, Mr. Liebman served as a Senior Finance Business Partner at Nucleus Global, a privately owned Medical Communications company. While at Nucleus Global, he oversaw nearly $35 million in revenue annually, in addition to the FP&A activities associated with that revenue. He began his career in the Municipal Finance and Mortgage Industries.

Mr. Liebman holds a B.S. Degree in Economics from Lehigh University.

Chief Financial Officer

Dr. Skoumbourdis serves as Context's Sr. Director, Program Management. She brings over 20 years of combined experience in discovery and translational research and integrated program management in biotech and pharma and has held project management roles of increasing responsibility for over 10 years. Prior to joining the Company, Dr. Skoumbourdis was Head of Project Management at Code Bio, where she led PMO and operational activities. She has held program management positions with Spark Therapeutics and Gyroscope Therapeutics, where she led IND-enabling studies for the company's second asset and was the business partner to the SVP of Technical Operations, supporting device development and alliance management for the manufacturing team. Dr. Skoumbourdis began her pharmaceutical career at Sandoz, Inc. a Novartis Company, where she served as the first scientific advisor for the intellectual property group.

Dr. Skoumbourdis earned a Bachelor of Science in Chemistry from The College of New Jersey and PhD in Synthetic Organic Chemistry from Pennsylvania State University. She was awarded an IRTA Postdoctoral Fellowship at The National Institutes of Health in Bioorganic and Medicinal Chemistry. 

Erin Zebrowski is the Senior Director of Quality at Context Therapeutics. She is responsible for all aspects of GMP/GCP/GLP quality for the organization. Erin has more than 15 years’ experience in the pharmaceutical industry in various analytical and quality assurance roles. Prior to joining Context, she has held various technical positions at Becton Dickinson, UPM Pharmaceuticals, Nutramax Laboratories, Eisai Inc., Epicur Pharma, and TG Therapeutics.

Erin holds a BS degree in Chemistry from York College of Pennsylvania and an MPS in Biotechnology (Regulatory Track) from University of Maryland Baltimore County.